Marshall Wace North America’s Antares Pharma, Inc. ATRS Stock Holding History

Marshall Wace North America’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-147,025	Closed	-$396K	–	1692
2020 Q3	$396K	Sell	147,025 -118,782	-45%	-$329K	﹤0.01%	1016
2020 Q2	$731K	Sell	265,807 -42,213	-14%	-$118K	﹤0.01%	849
2020 Q1	$728K	Buy	308,020 +256,533	+498%	+$873K	0.01%	682
2019 Q4	$242K	Buy	51,487 +33,312	+183%	+$136K	﹤0.01%	934
2019 Q3	$61K	Sell	18,175 -23,839	-57%	-$78.5K	﹤0.01%	1135
2019 Q2	$138K	Sell	42,014 -21	-0%	-$61	﹤0.01%	1061
2019 Q1	$128K	Buy	42,035 +21	+0%	+$68	﹤0.01%	1073
2018 Q4	$115K	Buy	+42,014	New	+$138K	﹤0.01%	1056
2017 Q3	–	Sell	-128,920	Closed	-$387K	–	1590
2017 Q2	$387K	Buy	+128,920	New	+$365K	﹤0.01%	1132

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Marshall Wace North America's ATRS Position: Q4 2020 in Review

Marshall Wace North America sold out of Antares Pharma, Inc. (ATRS) in Q4 2020, closing a stake of 147,025 shares — an estimated $396K sold.

Marshall Wace North America first reported a position in ATRS in Q2 2017 and held it in 9 quarters. The position peaked at $731K in Q2 2020. 174 funds tracked by Wall St. Rank hold ATRS as of Q4 2020.

Marshall Wace North America reported no remaining Antares Pharma, Inc. position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 147,025 Antares Pharma, Inc. shares in Q4 2020, an estimated $396K.
Marshall Wace North America first reported a position in Antares Pharma, Inc. in Q2 2017 and held it in 9 quarters.
Marshall Wace North America's Antares Pharma, Inc. position peaked at $731K in Q2 2020.
174 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.